Governance Concord Biotech Limited

CONCORDBIO

INE338H01029

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:19:41 15/07/2025 pm IST			5-day change	1st Jan Change
1,835.20 ^INR	-0.09%		+4.23%	-16.99%

08/07	Concord Biotech Limited, Q4 2025 Earnings Call, May 30, 2025
02/07	Stellon Biotech Inc announced that it has received $0.0015 million in funding from Concord Biotech Limited	CI

Executive Committee: Concord Biotech Limited

Manager

Positions heldSince

Sudhir Vaid

72 year

Chief Executive Officer

10/05/2000

Lalit Sethi

59 year

Director of Finance/CFO	14/03/2022
Investor Relations Contact	14/03/2022
Public Communications Contact	14/03/2022

Prakash Sajnani

Comptroller/Controller/Auditor

29/05/2025

Devang Bhatt

Sales & Marketing

10/02/2005

Ankur Sudhir Vaid

Chief Executive Officer

01/09/2011

Composition of the Board of Directors: Concord Biotech Limited

Director

CommitteesSince

Sudhir Vaid

72 year

Chairman

10/05/2000

Jayaram Easwaran

72 year

Compensation Committee	11/11/2019
Governance Committee	05/08/2019
Nominating Committee	11/11/2019
Audit Committee Chair	11/11/2019
Audit Committee	14/06/2022

Ravi N. Kapoor

62 year

Audit Committee Chair	27/02/2009
Audit Committee	07/12/2023
Compensation Committee Chair	07/12/2023
Nominating Committee Chair	07/12/2023

Amitabh Gajendra Thakore

80 year

Audit Committee Chair	31/01/2017
Compensation Committee Chair	31/01/2017
Nominating Committee Chair	31/01/2017

Mandayam Chakravarthy Sriraman

79 year

Compensation Committee	14/06/2022
Nominating Committee	14/06/2022

Bharti Khanna

57 year

Compensation Committee	31/01/2017
Nominating Committee	31/01/2017

Rajiv Ambrish Agarwal

54 year

Compensation Committee	08/05/2008
Nominating Committee	08/05/2008

Arvind Motilal Agarwal

65 year

Audit Committee

24/05/2022

Ankur Sudhir Vaid

Director/Board Member

01/09/2011

Latest Appointments: Concord Biotech Limited

Concord Biotech Limited Appoints Ms. Hina Patel as Company Secretary and Compliance Officer, Effective May 30, 2025	29/05	CI
Concord Biotech Limited Announces Resignation of Prakash Sajnani as Company Secretary & Compliance Officer, Effective May 29, 2024	13/05	CI
Concord Biotech Limited Announces Resignation of Utpal Hemendra Sheth as Independent Director	30/23/30	CI
Concord Biotech Limited Announces Resignation of Anil Katyal as Independent Director	25/23/25	CI
Concord Biotech Limited Announces Cessation of Amit Varma as Non-Executive Non-Independent Director	19/23/19	CI

More news

Former Officers and Directors: Concord Biotech Limited

Insider

Positions held

SinceUntil

Utpal Hemendra Sheth

Director/Board Member	04/12/2009	30/09/2023
Independent Dir/Board Member	04/12/2009	30/09/2023

Anil Katyal

Director/Board Member

23/10/2019

25/08/2023

Amit Varma

Director/Board Member

05/07/2016

19/08/2023

Rakesh Radheshyam Jhunjhunwala

Director/Board Member

22/12/2009

M. C. Srivastava

Chairman

Age distribution of managers

Parity Men Women

Male	13
Female	1

Of which Executive Committee

Male	5
Female	0

Of which Directors

Male	8
Female	1

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Companyâs offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.

Employees

1,377

Sector

Pharmaceuticals

Calendar

03/09 - Q1 2026 Earnings Release (Projected)

More about the company